Viking pays $150M to recruit CordenPharma for obesity drug manufacturing saga
Obesity upstart Viking Therapeutics has agreed to pay a total of $150 million through 2028 to enlist CordenPharma for production of its dual GIP-GLP-1 agonist VK2735. Under the deal, CordenPharma will crank out long-term supply of both the subcutaneous and oral versions of Viking’s experimental drug.
Obesity upstart Viking Therapeutics has agreed to pay a total of $150 million through 2028 to enlist CordenPharma for production of its dual GIP-GLP-1 agonist VK2735. Under the deal, CordenPharma will crank out long-term supply of both the subcutaneous and oral versions of Viking’s experimental drug.
